Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.
Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology and rare disease.
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.
Cookies that may not be particularly necessary for the website to function and are used specifically by Dynacure, as data controller, to collect user personal data via analytics are termed as non-necessary cookies. It is mandatory to procure your user consent prior to running these cookies on our website. After consenting, you may withdraw your consent at any time via the cookies page. Refusing these cookies will have no impact on your individual use of the website but will impact our ability to improve it for the benefit of future users.